ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO0854

Double Renal Pathology with Favorable Response to Pegcetacoplan in a Pediatric Patient: A Case Report

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Author

  • Alrasheed, Reem Saleh, King Fahad Medical City, Riyadh, Riyadh Province, Saudi Arabia
Introduction

MPGN is a rare histological pattern of immune-mediated kidney injury. It has recently been reclassified into two major subtypes: IC-MPGN and C3G. ARPKD is a chronic inherited disorder characterized by cystic kidney changes and a gradual decline in renal function.

Case Description

An 11-year-old girl who initially presented with nephrotic-range proteinuria, edema, hypertension, bicytopenia, and hepatosplenomegaly. Despite initial immunosuppressive therapy with steroids and MMF, her condition deteriorated. A biopsy confirmed IC-MPGN, and she developed progressive renal dysfunction requiring dialysis. Endoscopy revealed esophageal varices, and genetic confirmed ARPKD. In light of her refractory disease course, off-label treatment with pegcetacoplanwas initiated.
Following the initiation of pegcetacoplan, she experienced clinical and biochemical improvement. Her urine output progressively increased, creatinine decreased from 450 µmol/L to 129 µmol/L, and proteinuria declined from 6 g/day to 0.9 g/day. Dialysis was discontinued after 11 weeks.

Discussion

This case highlights a rare overlap of ARPKD and IC-MPGN, and demonstrates a favorable clinical response to pegcetacoplan following failure of conventional therapies. It supports a potential “double-hit” hypothesis and emerging role of complement inhibition in managing severe, treatment-resistant glomerular disease.

Digital Object Identifier (DOI)